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SUMMARY 
 
A 14-year-old, spayed female local dog was presented to University Veterinary Hospital-University Putra Malaysia (UVH-
UPM) for the complaint of uncontrollable seizures. The intracranial neoplasia or trauma as a cause of seizures was ruled out based 
on magnetic resonance imaging conducted prior to presentation. Full diagnostic investigation inclusive of haematology, serum 
biochemistry, parasitology, thoracic and abdominal radiography and abdominal ultrasonography was conducted. A diagnosis of 
insulinoma was made from the persistent, low fasting blood glucose levels and the inappropriately high fasting insulin level, as well 
as the response to treatment with prednisolone.  
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INTRODUCTION 
 
Insulinomas are functional beta-cell tumours of the 
pancreatic islet cells. The clinical signs are attributable to 
hypoglycaemia as a result of hyperinsulinaemia. It is 
uncommon in dogs and often undiagnosed (Garrett, 2003). 
Little is known about the survival times associated with 
the various medical treatments (Jaillardon et al., 2011). 
 
CASE REPORT 
 
A 14-year-old, spayed female local dog was referred 
to University Veterinary Hospital-Universiti Putra 
Malaysia (UVH-UPM) for seizures. Prior to  presentation 
to UVH,  an intracranial tumour or trauma as the cause of 
the seizures was ruled out by the referral practice based on 
magnetic resonance imaging of the brain, and the dog was 
treated with phenobarbitone 30 mg (1/4 tab, twice daily) 
for about one month with no clinical improvement. 
Physical examination revealed no remarkable findings 
except for bilateral immature cataracts. The following 
diagnostic tests were conducted: haematology and serum 
biochemistry, Ehrlichia canis IgG immunocomb test, as 
well as chest and abdominal radiography. A result of the 
complete blood count was normal while the serum 
biochemistry analysis results (Table 1) were non-specific 
and did not contribute towards determining the cause of 
seizures: 
 
Table 1. Abnormal serum biochemistry values for the 
dogs  
 
Biochemistry parameters Result Normal 
range 
Sodium (mmol/L) 108.3 140-155 
Chloride (mmol/L) 92.4 96-122 
Alanine aminotransferase (U/L) 159.6 5-90 
Alkaline phosphatase (U/L) 105 40-100 
Urea (mmol/L) 16.8 3.0-7.5 
 
 
*Corresponding author: Dr. Leong Zi Ping (Z.P. Leong); 
Email:leong0908@yahoo.com 
All radiographs were unremarkable. During the 
follow-up visit a week later, the fasting glucose level 
measured using a glucometer (ACCU-CHEK®) was 1.4 
mmol/L while the insulin level measured via direct 
chemiluminescent technology by Pathlab (Malaysia) was 
31.8 IU/L (220.85 pmol/L). Both the results strongly 
pointed to a diagnosis of insulinoma. Upon abdominal 
ultrasonography no masses or abnormal structures were 
detectable on the pancreas. Prednisolone 5mg (0.30 
mg/kg, 1/4 tab, twice daily) was started along with S-
Adenosyl-L-Methionine 75mg, (Samylin Small Breed, 
Vetplus), 10 mg/kg, 1 tab, once daily as a 
hepatoprotectant. The owner was instructed to provide 
small amounts of food and glucose syrup frequently to the 
dog to maintain normal blood glucose levels. For 6 
months since the diagnosis till present, the dog has not  
seizured. The liver enzymes such as ALT and ALP were 
also monitored closely to keep track of the extent of 
steroid hepatopathy in which the latest readings were 
286.0 U/L and 371 U/L, respectively. 
 
DISCUSSION 
  
Insulinoma or pancreatic islet cell tumour is a 
neoplasm that results in insulin overproduction, which is 
rarely diagnosed in dogs. Most insulinomas in dogs are 
adenocarcinomas. There are three stages of severity of 
insulinoma growth. In stage I, the tumour cells are 
confined to the pancreas whereas in stage II, the tumour 
cells are found both in the pancreas and the regional 
lymph nodes. In stage III, the tumour cells are found in 
distant metastatic sites such as intra-abdominal lymph 
nodes, liver, mesentery, and the omentum (McDermott, et. 
al., 1999; Garrett, 2003). 
Insulinomas are more often seen in medium and 
large dogs but there is no particular breed or sex 
predisposition (Kruth et. al., 1982; Mehlhaff et. al., 1985). 
Middle aged dogs around 8years old are most frequently 
affected (Rijnberk, 1996). 
The patient in this report was presented with 
weakness and seizures. These are the most common 
presenting signs  of dogs with insulinoma cases as 
reported by Garett (2003) where 60% of the cases showed 
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seizures, 45% weakness, 25% collapse or ataxia, 15-20% 
muscle twitching and/or lethargy and/or bizarre 
behaviour, 10% polydipsia, polyuria, and/or polyphagia, 
and 5% syncope. 
Most often, the diagnosis of an insulinoma is 
accomplished via the demonstration of a low blood 
glucose level at the same time a blood insulin level is 
found to be inappropriately elevated (Garett, 2003). From 
An insulin value of above 144 pmol/L with typical 
symptoms and concurrent hypoglycaemia (glucose below 
3.3 mmol/L) confirms the diagnosis of insulinoma 
(Feldman and Nelson, 1996). However, others have 
proposed a lower limit with insulin of ≥70 pmol/L and 
glucose level of below 3.5 mmol/L to be sufficiently 
diagnostic for insulinoma (Rijnberk, 1996). In this case, 
the patient had a fasting glucose level of 1.4 mmol/L and 
a fasting insulin level of 31.8 IU/L (220.85 pmol/L), 
which was within the above diagnostic thresholds.  
Insulinomas are typically small therefore, abdominal 
radiographs are usually unremarkable. Although 
abdominal ultrasound may reveal a mass in the pancreas, 
the detection rate by ultrasound is generally low, that is 
36% (Tobin et. al., 1999) and 56% (Trifonidou et. al., 
1998) in 2 respective studies. Nevertheless, most patients 
have microscopic or gross metastases to the intra-
abdominal lymph nodes, liver, mesentery, and omentum 
at the time of diagnosis (Garrett, 2003). However, we 
were unable to detect either the pancreatic mass nor any 
evidence of metastasis radiographically and/or 
ultrasonographically. 
Siliart (2004) reported an overall mean survival time 
of 11.9 (SD ± 0.8) months; 16.8 (SD ± 5.3) months with 
surgery, 12.5 (SD ± 1.1) months with medical treatment, 
17.8 (SD ± 4.8) months with surgery and concurrent 
medical treatment, and 2.5 (SD ± 0.9) months without 
treatment. 
Medical treatment includes the administration of 
glucocorticoids, diazoxide, and streptozotocin (Garett, 
2003). Glucocorticoids antagonize insulin at the cellular 
level, leading to decreased cell uptake and increased blood 
glucose, stimulate hepatic gluconeogenesis, and indirectly 
provide substrates for glycogenolysis. Diazoxide, a 
benzothiadiazide diuretic, works by inhibiting insulin 
secretion and cellular glucose intake, and stimulating 
gluconeogenesis and epinephrine release. Streptozotocin 
is a nitrosourea chemotherapeutic that is specifically toxic 
to beta cells, however, its effectiveness has yet to be 
proven (Garett, 2003). Prednisone alone or with diazoxide 
significantly improved the survival time compared to 
diazoxide alone or no medical treatment. There was no 
significant difference between prednisone and a 
combination of prednisone and diazoxide (Jaillardon, et 
al., 2011). While surgery allows for a definitive diagnosis 
and prolongs the survival time, the old age (14-year-old) 
and the risk of post-operative complications (such as 
pancreatitis and diabetes mellitus) outweighed the 
benefits, and hence glucocorticoids (prednisolone) was the 
treatment of choice for our patient. The prognosis for the 
disease is guarded to poor, depending on the degree of 
malignancy and stage of the tumour (Feldman and Nelson 
1996), regardless of whether it is managed medically or 
surgically. 
CONCLUSION 
 
Insulinoma is a pancreatic islet cell tumour which 
occurs in middle and old aged dogs, resulting in over-
production of insulin and subsequent hypoglycaemia. 
Therefore, seizures in dogs of this age group should raise 
suspicion of this neoplasm when intracranial causes, 
metabolic diseases and infectious diseases are ruled out.  
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